Navigation Links
Watson Announces New Name -- Actavis -- for Global Operations
Date:10/31/2012

PARSIPPANY, N.J., Oct. 31, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it will adopt a new global name – Actavis – effective in 2013. The Company said it will initiate a multi-year rebranding campaign for its facilities, operations and commercial presence, and will transition to trading under a new symbol on the New York Stock Exchange in 2013.

"When we announced the proposed acquisition of Actavis in April 2012, we immediately instituted an extensive and accelerated review of our global brand position and naming equities," said Paul Bisaro, President and CEO of Watson. "A pioneer at the dawn of the U.S. generic industry in 1984, the Watson corporate name was never registered globally. As we initiated our global expansion strategy in 2009, it became clear that we could not establish a single, unified market presence under the Watson brand."

"With our expansion into more than 60 commercial markets around the world, we recognized the many benefits of uniting our Company under one name to all stakeholders – customers, consumers, payers, institutions and shareholders and potential shareholders.  We initiated an extensive review of the name equities within our portfolio, as well as assessing the potential of more than 2,000 potential new names.  As this process progressed, it became clear that one of the many assets within the Actavis acquisition was a single name, trademarked and protected around the world.  It evokes powerful words: action, vision and strength, time-honored attributes of both Watson and Actavis.  Adopting the Actavis name on a global basis, for our generics, brands and biosimilars businesses, was a logical and cost-effective solution." 

Watson has also implemented a distinctive redesign of the Actavis name, which reflects the history of both Watson and
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cleveland Clinic and IBM Work to Advance Watsons Use in the Medical Training Field
2. Watson Announces Sale of Rugby OTC Product Trademark and Assets to Major Pharmaceuticals, a division of The Harvard Drug Group, LLC
3. Watson to Present at the 2012 Bank of America Merrill Lynch Global Healthcare Conference
4. Watson to Present at the Morgan Stanley 2012 Global Healthcare Conference
5. Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines
6. Watson and Actavis Receive FTC Second Request
7. Watsons Generic ARTHROTEC(R) Receives FDA Approval
8. Watson to Host Second Quarter 2012 Earnings Conference Call and Webcast
9. Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
10. Watson Announces Lidoderm® Patent Challenge Settlement
11. Watson to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 11 Phosphagenics,Limited ("Phosphagenics") (ASX: POH; AIM: PSG; ... their joint phase 2 human clinical,trial to establish ... of metabolic syndrome is advancing at three sites ... of study participants, the,double-blind phase 2 trial, which ...
... Feb. 11 ,Pharmion (Nasdaq: PHRM ) and ... Medicines Agency (EMEA) and the European Commission (EC),designated ... Orphan,Medicinal Product for the treatment of acute myelogenous ... require that the product be,intended for the treatment ...
Cached Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
(Date:7/30/2015)... ... , ... Google recently announced that it will be disclosing any incidents involving ... June 8, 2015 article published by Nasdaq , the powerful tech company maintains ... computer-driven cars, which such industry players as Tesla CEO Elon Musk believe may very ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, ... San Bernardino counties, today announced that Dr. Michael Demoratz, PhD, LCSW, CCM is ... a strong proponent of early access to palliative care services for the underserved ...
(Date:7/30/2015)... Philadelphia, PA (PRWEB) , ... July 30, 2015 , ... ... the hospital. In an effort to provide comfort to patients as well as visiting ... an innovative solution: free phone charging stations. , The stations - powered by ...
(Date:7/30/2015)... ... , ... Ross A. Clevens, MD, FACS has been reappointed by ... Surgery. This is Dr. Clevens’ second appointment by the prestigious school. Over ... strong presence and a valuable mentoring program for medical students. , ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... that the latest issue of Inclusive™ magazine, its multimedia publication focused on implant ... edition of the new issue, Volume 6, Issue 2, as well as past ...
Breaking Medicine News(10 mins):Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4
... 2008 - Despite the general success of left ventricular ... patients, implantation of these devices often leads to increased ... and immediately after surgery. A new study published in ... these complications may be significantly reduced by way of ...
... get politicians to act on health care reform is ... surveyed in an opinion poll,commissioned by the Catholic Health ... would be the most effective way to prompt action ... health,care reform would best get the job done. Twenty-two ...
... Fully Understand the Details ... of Their Health Insurance Plan, WESTLAKE VILLAGE, Calif., ... the U.S., yet,contacting plan members regularly and increasing their understanding of,plan ... business and additional sales of services to members,according to the J.D. ...
... ... ... PARIS, April 30 In order to give a,representation of our underlying economic performance, ... EPS (excluding selected items) in U.S. dollars(1) in order to,facilitate comparisons with the majority ...
... the cross hairs of radiation or chemotherapy may be ... jammed, say University of Florida scientists writing in a ... fly cells discovered that slight changes in the protein ... aptly named for their roles in triggering cell death ...
... LONDON, April 30 ,GlaxoSmithKline (NYSE: GSK ) today ... team. In a message to employees, Andrew,Witty, CEO designate, ... take effect on May 22nd when he assumes the ... these changes, Andrew Witty said: "It is,clear that our ...
Cached Medicine News:Health News:Voters Believe They Hold Power in Health Care Reform Debate 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 3Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 4Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 5Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 6Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 7Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 8Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 9Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 10Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 11Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 12Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 13Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 2Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 3Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 4Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 5Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 6Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 7Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 8Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 9Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 10Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 11Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 12Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 13Health News:'Destruct' triggers may be jammed in tumor cells, UF geneticists say 2Health News:GSK Announces Changes to Corporate Executive Team 2Health News:GSK Announces Changes to Corporate Executive Team 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: